Ozempic Copycat Makers Seek Block of FDA Drug Shortage Decision

Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, while a lawsuit plays out over whether the agency lawfully made that determination.

The Outsourcing Facilities Association and FarmaKeio Custom Compounding said it will suffer irreparable harm without an injunction against the Food and Drug Administration’s conclusion that Novo’s semaglutide shortage is resolved, the compounders wrote Thursday in a motion for preliminary injunction filed in the US District Court for the Northern District of Texas.

The FDA’s declaration on Feb. 21 meant that drug compounders—pharmacists, facilities, and others who ...